TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.